Mean change from baseline to week 96 in bone turnover markers by randomised arm (abacavir-lamivudine vs. tenofovir-emtricitabine).

<p><b>Note.</b> Error bars represent 1 standard deviation from the mean (<b>a</b>) <b>BALP</b>, bone-specific alkaline phosphatase; (<b>b</b>) <b>P1NP</b>, procollagen type 1 N-terminal propeptide; (<b>c</b>) <b>βCTx</b>, C-terminal cross-linking telopeptide of type 1 collagen; (<b>d</b>) <b>OPG</b>, osteoprotegerin; <b>ABC/3TC</b>, abacavir/lamivudine; <b>TDF/FTC</b>, tenofovir/emtricitabine. There was no significant between-group difference at any time point for RANK.